MoxDuo Takes A Fall Back; Advisory Committee Delayed By Data Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
QRxPharma’s preparations for the panel review uncovered issues with the timing of data collection at one of the sites in its pivotal trial. The company will resubmit likely in the fall.